Nasal irritation is a documented Semax side effect. Reliable rates for headache, anxiety and serious reactions aren't established. Small studies and incomplete reporting leave long-term safety uncertain. A short list of reported Semax side effects doesn't mean the risks are fully understood.
Semax is a peptide, a short chain of amino acids, the building blocks of proteins. Much of its human research comes from Russia. The medical uses studied for Semax help explain those studies' setting; they don't establish safety for someone using it for focus.
Semax side effects: what has been reported
The Russian prescribing information for registered Semax 0.1% nasal drops lists mild irritation of the nasal lining with prolonged use. It does not give a percentage or say how often irritation leads someone to stop treatment.
Two other figures appear in a 2013 review by Kolomin and colleagues in Neuroscience & Medicine. The discussion concerns 1% Semax in people with brain circulation disorders, including stroke.
| Report in the review | Reported frequency | What that number covers |
|---|---|---|
| Change in the color of the nasal lining | About 1 in 10 people (10%) | Patients described in the older 1% Semax literature |
| Mild blood sugar increase | About 7 in 100 people with diabetes (7.4%) | The diabetes subgroup, not everyone receiving Semax |
The review doesn't supply the patient counts behind those percentages in that passage. They are older reported figures, not reliable estimates for a current compounded spray, made by a pharmacy for a prescription.
A change in lining color also isn't the same finding as nasal irritation. Combining both under a single “10% irritation” claim changes what the source says.
For a prescription containing Semax and Selank, these single-ingredient findings are only part of the safety discussion. The blend needs its own assessment.
What small human studies can tell us
A 2014 study in Ophthalmology Reports enrolled 36 people with glaucoma, an eye condition that can damage the nerve carrying visual signals. Only 24 received Semax alongside their usual treatment; 12 continued usual treatment without Semax. At the one-month assessment, the authors reported no unwanted reactions to Semax.
That is a useful observation. But 24 treated people cannot establish how often uncommon problems occur, or what happens with months of repeated use.
A 1999 report in Anesteziol Reanimatol studied 73 patients with brain injury caused by a lack of oxygen. The authors reported unusual bursts of activity on EEG, a recording of the brain's electrical activity, after Semax administration in some cases.
They did not give the number affected. The report cannot provide a seizure rate for healthy users, but it adds a reason for careful review of seizure history.
These studies answer narrower questions than “is Semax safe?” Different illnesses, other treatments and short follow-up limit what transfers to another patient.
What the July 2026 FDA safety review adds
As of September 30, 2026, the day this article was written, FDA's July 24, 2026 presentation described substantial gaps in Semax safety data. Seven of the eight references in its safety table did not discuss health problems during treatment. Silence about side effects isn't evidence that none occurred.
FDA also raised concerns about possible bleeding risk and unwanted immune reactions related to peptide clumping or impurities. The review did not establish how often those problems occur.
Its briefing document described a consumer report of eye pain and burning after online-purchased nasal drops in May 2024. The consumer reported hospitalization and continuing eye pain in May 2025. A voluntary report alone cannot establish that Semax caused the symptoms or calculate their frequency.
Semax's regulatory history explains the separate compounding review.
Can Semax cause anxiety or headaches?
Published human sources don't give dependable rates for either symptom. A new headache or change in anxiety still deserves attention; timing alone doesn't identify the cause.
The Russian 0.1% label lists anxiety-related disorders and a history of seizures as reasons not to use that medicine. Those restrictions are different from measured side-effect rates. They don't show that everyone develops anxiety or seizures.
Interaction questions matter too. A 2005 rodent study in Neurochemical Research found that Semax amplified some effects of amphetamine. That is an animal finding, not a demonstrated interaction rate in people.
Stimulants and medicines that increase bleeding risk belong in the prescriber's review, along with other prescriptions and supplements. A Semax/Selank prescription needs that same medication review; adding another peptide doesn't resolve the missing safety data.
Semax nasal spray side effects and modified versions
Intranasal means delivered through the nose. The Russian drops and a compounded spray can differ in concentration, other ingredients and how much each application delivers. Their safety findings aren't automatically interchangeable.
Standalone Semax is coming soon to Promise as a compounded nasal spray — add me to the list; Promise offers the Semax/Selank blend as a compounded injectable — 1 mg / 1 mg per mL × 5 mL vial (5 mg Semax + 5 mg Selank) — after a licensed provider reviews your request. The safety discussion therefore needs to match the actual prescription, including every ingredient in it.
A compounded Semax formulation is different from an FDA-approved product and is not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
N-acetyl Semax amidate is a chemically modified version of Semax. Studies of standard Semax don't establish that version's side effects or show it is safer. A changed name or chemical structure doesn't answer the human safety question.
Likewise, evidence about the separate compounds doesn't establish that a blend reduces unwanted effects. The Semax and Selank comparison explains their differences; the combination still needs separate evidence.
Symptoms that need prompt care
Severe eye pain, pain that persists, or pain with reduced vision needs prompt medical assessment, as MedlinePlus explains. These symptoms shouldn't be dismissed as ordinary nasal irritation.
Trouble breathing, swelling of the throat or tongue, and fainting can signal a severe allergic reaction. This requires emergency care, including calling 911 in the United States (MedlinePlus). These are general emergency signs, not a measured list of common Semax reactions.
For a Semax/Selank prescription, the follow-up plan should identify who receives a suspected-reaction report and how urgent symptoms are handled.
What the prescriber needs to review
A useful review starts with the exact formulation and a complete medication list. It also covers diabetes, bleeding problems, seizure history, mental health, allergies, pregnancy and breastfeeding. The Russian label excludes pregnancy and breastfeeding because clinical studies were not conducted.
Existing symptoms matter. A headache that started before a prescription is different from one that appeared afterward. The clinician needs the timing, severity and any other medication changes to assess a possible reaction.
Follow-up also needs a way to identify the dispensed product: the pharmacy, ingredients, strength and batch number. That makes a reaction report specific to a bottle. It still takes clinical assessment to decide whether the formulation, another medicine or the underlying condition explains the symptoms.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The provider sets any dose and decides when to reassess. A licensed pharmacy and an identifiable care team provide accountability; they don't remove the gaps in Semax's safety evidence.
